FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain
For Immediate Release: January 30, 2025
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces ... [3366 chars]
Source: FDA.gov
